purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation nvo earnings call period ending december image source motley fool novo nordisk nvo q earnings calljan etcontents prepared remark question answer call participant prepared remark operatorgood day thank standing welcome q novo nordisk earnings conference call time participant listenonly mode speaker presentation questionandanswer session operator instruction please advised today conference recorded would like hand conference speaker today daniel bohsen cvp investor relation please go aheaddaniel bohsen head investor relation welcome novo nordisk earnings call full year outlook name daniel muusmann bohsen head investor relation novo nordisk today ceo novo nordisk lars fruergaard jorgensen executive vice president head commercial strategy corporate affair camilla sylvest executive vice president head north america operation doug langa executive vice president head development martin holst lange finally chief financial officer karsten munk knudsen speaker available qa session today announcement slide call available website novonordiskcom please note call webcast live recording made available website well call scheduled last one hour please turn next slideshould invest novo nordisk right buy stock novo nordisk consider motley fool stock advisor analyst team identified believe best stock investor buy novo nordisk one stock made cut could produce monster return coming year stock advisor provides investor easytofollow blueprint success including guidance building portfolio regular update analyst two new stock pick month stock advisor service tripled return sp since see stock stock advisor return january presentation structured outlined slide please note sale operating profit growth statement constant exchange rate unless otherwise specified please turn slide need advise call contain forwardlooking statement subject risk uncertainty could cause actual result differ materially expectation information risk factor please see company announcement full year slide prepared presentation lars update strategic aspiration lars fruergaard jorgensen president chief executive officer thank daniel please turn next slide delivered doubledigit sale operating profit growth continue make progress strategic aspiration walk performance highlight handing word colleague continue making progress purpose sustainability carbon emission carbon emission decreased compared prepandemic level reached million patient diabetes obesity treatment uphold commitment sustainable employer expanded number woman senior leadership position compared end past year developed expanded pipeline across therapy area diabetes obesity seen several exciting trial readout advanced novel asset phase also expanded footprint cardiovascular disease strengthened latestage pipeline rare blood disorder martin come back overall rd milestone later achieved two major milestone within commercial execution reached obesity sale operation billion danish krone aspiration diabetes achieve onethird global diabetes value market going forward continue aim treating patient innovative treatment lastly pleased strong sale growth operating profit growth measured constant exchange rate would like hand word camilla give u latest update commercial executioncamilla sylvest executive vice president head commercial strategy corporate affair thank lars please turn next slide total sale increased sale growth driven operating unit north america operation growing international operation growing glp sale diabetes increased driven north america growing international operation growing insulin sale decreased driven declining sale yous region china obesity care sale grew international operation sale grew driven saxenda wegovy sale saxenda increased sale wegovy reached around billion danish krone going forward continue roll wegovy sustainable manner volume cap launch balance supply demand north america operation obesity care sale grew total rare disease sale decreased driven decrease international operation decrease north america operation following reduction supply norditropin please turn next slide sale growth diabetes care growing faster total diabetes market result global diabetes value market share increased strategic aspiration reaching onethird global diabetes value market increase reflects market share gain north america operation international operation please turn next slide international operation total diabetes case increased primarily driven glp sale growing novo nordisk market leader international operation glp value market share ozempic continues glp market leadership market share rybelsus shy value market share driven solid uptake across geography hand word dougdoug langa executive vice president head north america operation thank camilla please turn next slide yous sale growth glp diabetes treatment driven expansion market versus fourth quarter prescription volume growth glp class compared fourth quarter measured total prescription novo nordisk continues market leader around market share please turn next slide obesity care sale grew driven operating unit volume growth global branded obesity market doubled volume growth international operation obesity care sale driven strong saxenda performance wegovy launch seven international operation country yous sale wegovy grew reflecting commercial relaunch january safeguard continuity care reduced release lowerdose strength back may continued throughout remainder last year pleased state enabling new yous patient initiate treatment doubling amount lowerdose strength wegovy compared previous month gradually increasing overall supply throughout remainder please go next slide rare disease sale decreased sale decrease driven sale decline north america operation sale decline international operation sale rare blood disorder increased driven launch product hemophilia b partially countered novoseven sale rare endocrine disorder product decreased reflecting reduction manufacturing output martin update rdmartin lange executive vice president head development thank doug please turn next slide first pleased share exciting headline result combine trial onceweekly icosema combine free week openlabel treattotarget phase trial comparing onceweekly icosema oncedaily insulin glargine u together four daily injection insulin aspart also called basalbolus insulin treatment objective combine assist efficacy safety onceweekly icosema people type diabetes poorly controlled daily basal insulin trial achieved primary endpoint demonstrating noninferiority reducing ac week onceweekly icosema compared insulin glargine u together insulin aspart overall ac baseline onceweekly icosema achieved estimated reduction hbac percentage point compared percentage point insulin glargine together insulin aspart people trial baseline body weight kilogram treatment icosema achieved superior reduction body weight weight loss kilogram icosema compared kilogram weight gain basal insulin basalbolus treatment estimated treatment difference kilogram icosema also showed superiority insulin glargine u together insulin aspart term severe clinically significant hypoglycemic event event per patient year exposure compared event per patient year exposure basalbolus treatment arm overall icosema appear safe welltolerated profile phase result onceweekly icosema promising people poorly controlled type diabetes basal insulin icosema potential streamline insulin intensification addressing main patient barrier icosema set new standard onceweekly treatment reducing annual injection around injection substantial reduction patient burden provided together strong glycemic control proper weight management importantly factor time lower rate hypoglycemia compared current gold standard insulin basalbolus treatment please turn next slide turning upcoming rd milestone many exciting trial result however get would like highlight milestone fourth quarter within obesity successfully completed two phase study semaglutide milligram addressing obesityrelated comorbidities well phase trial oral amycretin first step trial phase knee osteoarthritis trial investigated effect semaglutide milligram onceweekly coprimary endpoint body weight western ontario mcmaster university osteoarthritis index abbreviated womac selfadministered measurement used assessing pain functionality trial people obesity mild moderate knee osteoarthritis enrolled study achieved coprimary endpoint demonstrating superior reduction womac pain score well inbody weight semaglutide milligram compared placebo estimated reduction mean womac pain score baseline week semaglutide milligram placebo estimated treatment difference statistically significant also considered clinically relevant trial result serve foundation potential outcome trial future obesity asset addition successfully completed step hfpef diabetes trial step hfpef diabetes trial investigated impact semaglutide treatment functionality symptom patient obesity type diabetes established heart failure total people enrolled study coprimary endpoint average change baseline kansa city clinical summary score questionnaire body weight trial semaglutide showed point improvement versus placebo arm week mean change point favor semaglutide considered clinically relevant solid result chronic heart failure superior reduction body weight also observed semaglutide milligram versus placebo submitted result step hfpef obesity trial well type diabetes trial regulatory review yous europe course january mark another milestone ongoing effort address unmet medical need patient overweight obesity established cardiovascular disease last highlight fourth quarter successful completion oral amycretin phase trial appeared safe welltolerated profile amycretin decided september also initiate phase trial oneweekly subcutaneous amycretin expect advance amycretin clinical development moving forward within diabetes care expect decision approval insulin icodec europe japan china well yous second half also anticipating exciting result combine combine icosema development program initial half note expecting phase result onceweekly glpgip first half initiated phase trial oncemonthly glpgip course january continue build evidence semaglutide molecule within diabetes well subcutaneous semaglutide milligram anticipate readout flow people type diabetes chronic kidney disease first half year followed functional outcome trial stride people type diabetes peripheral artery disease second half far semaglutide cardiovascular outcome study soul expected completed second half getting semaglutide people diabetes cardiovascular disease obesity area expect fda decision approval select data submission first half furthermore look forward first phase readout cagrisema toward turn year last highlight excited upcoming readout mim phase first half mim novel nextgeneration factor viii mimetic antibody potential improved patient outcome reduced burden treatment people hemophilia karstenkarsten munk knudsen executive vice president chief financial officer thank martin please turn next slide sale grew danish krone constant exchange rate driven operating unit gross margin increased compared driven positive product mix following increased sale injectable glpbased treatment cost related ongoing capacity expansion negative currency impact lower realized price mainly yous region china partially offset effect sale distribution cost increased danish krone constant exchange rate increase driven operating unit north america operation cost increase driven relaunch wegovy promotional activity ozempic international operation cost increase driven promotional activity rybelsus well obesity care market development activity furthermore increase sale distribution cost impacted adjustment legal provision research development cost increased measured danish krone constant exchange rate increase reflects strategic objective expand pipeline across therapy area specifically continue increase latestage clinical trial early research activity acquisition forma therapeutic inversago pharma also increased rd spending administration cost increased measured danish krone constant exchange rate operating profit increased measured danish krone constant exchange rate reflecting sale growth net financial item showed gain billion danish krone compared net loss around billion krone last year effective tax rate compared consequently net profit increased diluted earnings per share increased danish krone free cash flow realized billion danish krone compared billion line strategic aspiration deliver attractive capital allocation shareholder cash conversion positively impacted timing payment rebate yous provision related revised three b distribution policy also yous capital expenditure property plant equipment billion danish krone compared billion primarily reflects investment additional capacity active pharmaceutical ingredient production finished capacity current future injectable oral product please go next slide expect increase capital expenditure around billion danish krone significant stepup compared reflects expansion supply chain includes previously communicated expansion manufacturing facility kalundborg hillerod located denmark chartres based france increase capital expenditure mainly relates investment additional capacity active pharmaceutical ingredient production finished capacity current future injectable oral product across strategic therapy area coming year capital expenditure sale ratio still expected low double digit next slide please line strategic aspiration deliver attractive capital allocation shareholder returned billion danish krone shareholder via share buyback dividend end general meeting march st board director propose final dividend danish krone total dividend danish krone including interim dividend paid august increase compared making th consecutive year increasing dividend per share addition dividend billion danish krone share buyback past month concluded board director approved new share repurchase program dkk million executed coming month next slide please continue continued growth momentum expect sale growth constant exchange rate based several assumption described company announcement guidance reflects expectation sale growth north america operation international operation sale growth expected mainly driven volume growth glpbased treatment obesity diabetes care expectation continued volume growth capacity limitation outlook also reflects expected continued periodic supply constraint related drug shortage notification across number product geography expect operating profit grow constant exchange rate primarily reflects sale growth outlook continued investment future current growth driver within research development commercial reported sale expected percentage point lower constant exchange rate operating profit expected percentage point lower constant exchange rate expect net financial item amount gain around billion danish krone mainly reflects gain associated foreign exchange hedging contract well interest rate gain cash marketable security free cash flow expected billion billion danish krone reflecting sale growth favorable impact rebate yous countered investment capital expenditure cover outlook back larslars fruergaard jorgensen president chief executive officer thank karsten please turn final slide pleased strong performance reflects million people benefiting innovative diabetes obesity treatment continue make progress strategic aspiration focus continued significant expansion production capacity reaching patient progressing expanding pipeline would like hand word back danieldaniel bohsen head investor relation thank lars next slide please ready qa kindly ask participant limit one maximum two question includes subquestions operator ready take first question question answer operatoroperator instruction take first question one moment please first question come line mike nedelcovych td cowen please go aheadmike nedelcovych td cowen analyst thank question two martin first glpgip dual agonist relates clinical profile oncemonthly injection seems navigating gi toxicity titration phase drug board entire month could tricky think valid concern might undercut extent convenience advantage second question oral amycretin provide insight efficacy saw phase trial reasonable ambition would weight loss approach delivered cagrisema via oral route close amycretin get profiledaniel bohsen head investor relation thank mike martin youmartin lange executive vice president head development yeah thank thank question first oncemonthly glpgip honestly speaking asked question move oncedaily onceweekly focus titration proper titration mitigate gi tolerability side effect therefore quite confident manage oncemonthly setting actually see increase moving oncedaily onceweekly expect see moving onceweekly oncemonthly amycretin disclosing phase data obviously read fact stating progressing development also mean believe amycretin properly differentiated whatever else theredaniel bohsen head investor relation thank mike thanks early next question pleaseoperatorthank take next question one moment please next question come line peter verdult citigroup please go aheadpete verdult citi analyst yeah thanks pete verdult citi two question please lars karsten mentioned many time novo management priority scaling supply want try marry comment provided guidance mean annualize exit run rate q pretty much bottom end guidance realize fx rebating consider want push luck try get handle significantly capacity increase especially light select coming label year likely increasing demand secondly karsten quickly revenue recognition b pharmacy know currently partially revenue recognize baked guidance thought chance could change given prevailed litigation hhs could change stance b right fully revenue recognize could actually quite meaningful uplift novo earnings around thank youdaniel bohsen head investor relation thank pete karsten two question youkarsten munk knudsen executive vice president chief financial officer yeah first guidance important point continuing growth trajectory showed already remind sale growth adding tune million people novo nordisk product month period believe significant scaling round number talking magnitude look scaling next year similar type scaling like necessarily logic multiplying q four chronic disease business ups down currency inventory one quarter make dangerous annualize based three month growth platform remain rybelsus ozempic wegovy scaling three platform give u guidance provided today b right state partially recognizing b revenue linked accounting standard order recognize revenue accountant author call highly probable backdrop behind yes prevailed case back january still two case outstanding different jurisdiction around question would key informative point u decide proceed forward visavis accounting recognition spacedaniel bohsen head investor relation thank pete thank karsten next question pleaseoperatorthank take next question one moment please next question come line louise chen cantor please go aheadlouise chen cantor fitzgerald analyst hi thank taking question first question think launch lillys zepbound guidance second question expect report data nash mash study essence study fgf thank youdaniel bohsen head investor relation thank louise karsten give first guidance martin later mashkarsten munk knudsen executive vice president chief financial officer yeah always forecasting take account demand market competition supply capacity factor weighed guidance term pricing environment yous maintain high degree formulary access pbm basis volume basis would say question supply capacity since competing share given magnitude marketsdaniel bohsen head investor relation thank karsten martinmartin lange executive vice president head development yeah thank much essence mash study expect see readout around turn year progress toward regulatory filing fgf study phase trial actually also investigating effect icosema nash see readout little bit laterdaniel bohsen head investor relation thank martin ready next questionoperatorthank take next question one moment please next question come line sachin jain bank america please go aheadsachin jain bank america merrill lynch analyst thanks taking question sachin jain bank america firstly amycretin back martin plan progress commentary vague particularly oral formulation going ask vague moment factor go decision one would assume oral cagrisema would exciting commit waiting second question supply thank color doubling lower dos wegovy coming month assume ability supply lower dose doubling limit full year thank youdaniel bohsen head investor relation thank sachin martin first karsten take supply questionmartin lange executive vice president head development thank much sachin sure vague saying communicating phase data think hear see see u progress data confirm subcutaneous also potentially oral reason pursuing phase obviously providing optionality see big demand need provide flexibility optionality oral subcutaneous providing come efficacy heard u say number time stay want see differentiated product go subcutaneous oral marketplace seen far amycretin brings u confidence amycretin oral subcutaneous see data potentialkarsten munk knudsen executive vice president chief financial officer yeah sachin thank wegovy question little bit precise wegovy done increased supply starter dose double taken place also previously communicated continue gradually expand supply starter dos well dose strength gradually scale scaling supply capacity sustainable supply chain place including necessary inventory avoid stopgo pattern saw pastsachin jain bank america merrill lynch analyst thank youdaniel bohsen head investor relation thank thank question ready next set questionsoperatorthank take next question next question come line martin parkhoi seb please go aheadmartin parkhoi skandinaviska enskilda banken analyst great thank much two question firstly regional development know saw big imbalance year least especially fourth quarter north america international relation see going expect get know precise number word compared relation guidance second question reprioritization among thing removing levemir yous market far actually go cynical prioritize le insulin course production capacity glp franchisedaniel bohsen head investor relation thank martin karsten first question related guidance regional last portfolio participationsmartin lange executive vice president head development yeah regional dynamic would say classic dynamic people followed company extended period time type seasonality talking growth driver remain rybelsus wegovy ozempic real difference saw actually glp diabetes growth level similar north io north america fundamental difference pace wegovy rollouts course north america rolling ahead io important note launching additional io market volume cap way wegovy expect north america still rolling higher pace iodaniel bohsen head investor relation thank karsten lars youlars fruergaard jorgensen president chief executive officer yeah thank martin portfolio participation think see u committed people living diabetes need insulin look levemir specifically yous situation know tresiba well launching weekly insulin also see dynamic lost contract levemir u stay committed patient also leading u thinking carefully say optimal way treating patient efficacious product glp also optimization moving patient daily treatment weekly treatment get higher efficacy obviously easier produce presentation reduce number injection presentation needed going say social responsibility visavis patient still optimizing degree benefit patient ability scaledaniel bohsen head investor relation thank lars thank martin take next questionoperatorthank one moment please next question come richard vosser jpmorgan please go aheadrichard vosser jpmorgan chase company analyst hi thanks taking question two question please first question could update payer discussion around select see rebate pressure obesity franchise given still supply constrained particularly yous second question also thinking diabetes seen know consistent sort rebate pressure yous around ozempic rybelsus type side think pressure going thanks muchdaniel bohsen head investor relation thank richard doug give word select payer discussion say also competitive dynamic within diabetesdoug langa executive vice president head north america operation yeah thank question richard really appreciate reiterate super excited potential select data eagerly await whole full label update coming month know normal preparation think mean certainly part access know hopeful select unlock access know end even excellent data likely going happen overnight know end believe select set sema milligram apart first aom showing consistent benefit across endpoint including mace know super excited daniel bohsen head investor relation second part doug question regard competitive dynamic glp diabetes spacedoug langa executive vice president head north america operation yeah overall know see stable competitive environment obviously see increase volume expect see also decrease price time product get larger marketplace stable competitive market environment havedaniel bohsen head investor relation thank doug thank richard question next question pleaseoperatorthank one moment please next question come harry sephton ubs please go aheadharry sephton ubs analyst brilliant thank much taking question maybe first question back doug mentioned seen stable competitive environment yous wanted question whether observed change formulary position ozempic yous whether impacted prescription growth ozempic fourth quarter second question stay time therapy patient firstly update seeing wegovy also whether observed stay time ozempic changed last year might driving thank youdaniel bohsen head investor relation thank harry doug comment formulary status key product stay time give camilladoug langa executive vice president head north america operation yep thanks harry overall see major change formulary status glps know recall unrestricted access favorable access see largely unchanged yearcamilla sylvest executive vice president head commercial strategy corporate affair stay time say generally see better stay time wegovy seen previous antiobesity treatment like saxenda basically see fewer patient dropping still early day wegovy interrupted supply country also say yous also denmark see strong indication stay time longer wegovy especially denmark see majority patient initiated treatment beginning last year stayed treatment throughout year ozempic generally see continued long stay time tune four five year major change thatdaniel bohsen head investor relation thank camilla doug thanks question harry take next questionoperatorthank one moment please next question come line emily field barclays please go aheademily field barclays analyst hi thank ask two question first guidance range revenue growth constant exchange rate quite wide delta could give u color driver primarily cadence wegovy supply coming online anything else particularly play another question commercial coverage united state know pretty consistently indicated commercial slice employer yous opt expecting major change thank youdaniel bohsen head investor relation thank emily sound bit bad think got question karsten color guidance range later doug coverage wegovy youskarsten munk knudsen executive vice president chief financial officer thank question emily yes correct guidance range broader normally point time course plan narrow guidance range year time progress reason chosen broaden likely basically dynamic seen past quarter even dynamic market constrained supply growth net adjustment linked yous growth net model fundamentally major fundamental change seen prior quarter felt prudent beginning year start much wider guidance rangesdaniel bohsen head investor relation thank karsten doug comment coverage wegovy yous employer optindoug langa executive vice president head north america operation yep thanks emily still continue enjoy broad market access wegovy communicated equates around million people living obesity covered overall optins optouts continue see improvement net coverage focus continuing secure coverage time keep continuing grow volume market overall pleased level access looking forward improving timedaniel bohsen head investor relation thank much doug thanks emily question next question please operatorthank one moment please next question come line seamus fernandez guggenheim security please go aheadseamus fernandez guggenheim partner analyst thanks much question couple glpgip help u understand technology using extend halflife oncemonthly trying get better understanding likelihood confidence delivering monthly profile well efficacy profile given plan work inaudible oral amycretin molecule womac score help u understand womac score kind compare oa study treatment regimen dropin pain medication like naproxen medication like allowed separation occurred despite thanksdaniel bohsen head investor relation thank seamus question martin give word youmartin lange executive vice president head development yeah thank much first oncemonthly obviously know phase one number track pursuing space technology share point time broadly speaking confident happy research progress space obviously take asset phase one without level confidence broad applicability success womac sort broad applicability see point change baseline clinically relevant space saw point improvement term concomitant medication allowed specifically control group study actually also saw improvement placebo arm improvement seen semaglutide beyond space statistically significant well clinically relevantdaniel bohsen head investor relation thank much martin thanks seamus next question pleaseoperatorthank one moment please next question come line simon baker redburn atlantic please go aheadsimon baker redburn partner analyst thanks taking question two may please firstly capex wonder could give u sort idea billion investment start come stream api manufacturer film finishing indication run rate thereafter secondly question recent eracal collaboration wonder could give u reasoning choosing accessing platform specific molecule licensed namely era thanks muchdaniel bohsen head investor relation first karsten capexkarsten munk knudsen executive vice president chief financial officer yeah simon reframing question slightly taking point estimate making time series think necessarily optimal way would say good chunk capex spending year project already initiated earlier noted announced capex tune billion lifetime project course key element billion term coming stream gradually time api bigger ticket item see api coming stream already additional api capacity coming stream already different capacity coming online pretty much every year across manufacturing footprintsdaniel bohsen head investor relation thank karsten thank simon regard recent collaboration point time much add use opportunity bit advertisement upcoming capital market day talk early research partnership happy address next question pleaseoperatorthank next question come line mark purcell morgan stanley please go aheadmark purcell morgan stanley analyst yeah thanks taking question question number one wegovy yous fillandfinish line think moved one three line course could help u understand many line might added cadence addition course secondly shift weight surrogate marker outcome becoming important much assessing key product attribute cagrisema amycretin confidence show outcome benefit semaglutide future clinical developmentdaniel bohsen head investor relation wegovy karsten martin later outcome trial future obesity pipeline productskarsten munk knudsen executive vice president chief financial officer hi mark wegovy cmo filling say track previously communicated three cmo line think prudent continue specify number line location potential cmos say continue expand capacity year come given significant unmet need seeing unfortunately impute guidance scalability scaling supplymartin lange executive vice president head development specifically cardiovascular benefit pipeline product visavis semaglutide example know cagrisema right rely biomarkers cagrisema obviously superior body weight potential superior glycemic control also superior example blood pressure lowering lipid lowering potentially relevant cardiovascular biomarkers give u lot confidence cagrisema associated quite profound benefit cardiovascular space obviously show phase know currently running redefine study effectdaniel bohsen head investor relation thank martin thank mark time two set question kept brief let u try squeeze inoperatorthank next question come line richard parkes bnp paribas exane please go aheadrichard parkes exane bnp paribas analyst hi thanks taking question quick guidance capacity think last year consistently stated top end guidance necessarily magic ceiling term capacity manufacture wonder still case whether wider range suggests bullish top end push bit capacity expansion plan mean quite clear fillfinish expansion wegovy understanding flextouch optimizing already waypoints give investor around might able move seeing inflection around rather optimizing capacity currently thank youdaniel bohsen head investor relation karsten youkarsten munk knudsen executive vice president chief financial officer yeah thanks richard question guidance range important reiterate realistic outlook providing market thought could grow faster realistically would providing guidance point time expect normal distribution expect something around mid range work important note supply constrained environment important u order manage business sustainable way focus supply chain ensure resilient get bump saw past stopgo type decision important sustainable supply chain factor also likely range course job run company best possible manner entail driving topline growth well resilient supply chain setup scaling flextouch say entail cartridge filling assembly pack say scaling ongoing basis active project area want get detail externally around project plan would point recently announced expansion chartres dkk billion tap directly expanding pipeline example significant capex project extentdaniel bohsen head investor relation thank richard question thank karsten take one final questionoperatorthank one moment please final question come line michael novod nordea please go aheadmichael novod nordea market analyst thank much two brief question first oral amycretin previously saying ambition sort create oral cagrisema still sort ambition given question oral amycretin secondly program lillydirect sort direct consumer le something novo considering well given could sort significant untapped potential private market thanksdaniel bohsen head investor relation good martin brief comment amycretinmartin lange executive vice president head development yeah high level short answer yes obviously aspiration differentiated product amycretin oral amycretin range see efficacy safety cagrisemadaniel bohsen head investor relation thank martin doug comment competitive commercial strategy light competitor movementdoug langa executive vice president head north america operation would say bring back u say know believe foundation novocare lot element continue stay focused appreciate questionsdaniel bohsen head investor relation thank michael thank doug answer concludes qa session thank participating please feel free reach investor relation followup question close call always would like hand lars final remarkslars fruergaard jorgensen president chief executive officer yeah thank daniel also thank participating today hope clear pleased performance past year equally excited based attractive guidance range put forward lot focus scaling capacity real tangible backing scaling form doubling start dos yous look continuously expand capacity equally important expansion pipeline really doubling stronghold diabetes obesity also increasingly cardiovascular disease rare blood disorder excited pipeline shaping thank attention today look forward see near future byeoperatorthis concludes today conference call thank participating operator signoff duration minutescall participantsdaniel bohsen head investor relationslars fruergaard jorgensen president chief executive officercamilla sylvest executive vice president head commercial strategy corporate affairsdoug langa executive vice president head north america operationsmartin lange executive vice president head developmentkarsten munk knudsen executive vice president chief financial officermike nedelcovych td cowen analystpete verdult citi analystlouise chen cantor fitzgerald analystsachin jain bank america merrill lynch analystmartin parkhoi skandinaviska enskilda banken analystrichard vosser jpmorgan chase company analystharry sephton ubs analystemily field barclays analystseamus fernandez guggenheim partner analystsimon baker redburn partner analystmark purcell morgan stanley analystrichard parkes exane bnp paribas analystmichael novod nordea market analyst nvo analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool recommends novo nordisk motley fool disclosure policy